<DOC>
	<DOCNO>NCT00709228</DOCNO>
	<brief_summary>To determine relapse rate 24 week follow Hepatitis C Virus Genotype 1 Low Viral Load ( HCV LVL G1 ) patient treat 24 week Peg Intron Rebetol Hepatitis C Virus-Ribonucleic Acid ( HCV-RNA ) negative treatment week 4 week 24 . To determine proportion patient ( % ) sustain virological response 24 week post follow treatment .</brief_summary>
	<brief_title>Study Patients With Chronic Hepatitis C Infected With HCV LVL G1 Effect Peg-Intron Plus Rebetol Treatment ( Study P04793 )</brief_title>
	<detailed_description>Approximately 500 patient 100 site identify HCV LVL G1 patient</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Willingness participate 18 year old , either gender , race Must Hepatitic C Virus Low Viral Load [ LCV LVL ] ( positive , &lt; 600,000 IU/mL assay use individual study site . Only Hepatitis C VirusRibonucleic acid/quantitative polymerase chain reaction [ HCVRNA/qPCR ] assay result IU/ml acceptable ) AND diagnose Genotype 1 Subject consider suitable treatment per local label Investigator consider suitable subject consent treat Does show negative polymerase chain reaction [ PCR ] week 4 Pregnant woman plan become pregnant sexual partner woman plan become pregnant Subject qualify base contraindication , special warning , special population , and/or pregnancy &amp; lactation section Summary Product Characteristics [ SmPC ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>